News Medical1d
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The EMBO Journal1d
LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
emjreviews.com1d
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
University of California1d
Breast cancer treatment advances with light-activated ‘smart bomb’
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
Managed Healthcare Executive1d
Blood or Marrow Transplant Recipients Face Higher Skin Cancer Risk, Study Shows
Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...
PharmiWeb5d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...